R oche's (OTCQX:RHHBY) Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with ...

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to ...

I look forward to broadening Susvimo's impact to even more patients in my clinic." Approval of Susvimo was granted to Genentech.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA for ...

“Susvimo presents a unique ... initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group.

San Francisco, California–based Genentech, has potent antitumor activity. More than half the patients with advanced and inoperable skin cancer treated with GDC-0449 responded to treatment (New Engl.

Susvimo is the first and only continuous delivery treatment ... Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly ...

Roche announced that the US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss ...